TY -的T1 Levodopa-Carbidopa单药治疗的安全性和有效性晚期帕金森症患者(P2.046) JF -神经学乔-神经学六世- 90 - 15补充SP - P2.046 AU -詹姆斯·博伊德盟辛迪Zadikoff Jorge Zamudio 首页AU -珍妮Benesh盟盟——威宁Robieson盟Pavnit Kukreja Y1 - 2018/04/10 UR - //www.ez-admanager.com/content/90/15_Supplement/P2.046.abstract N2 -目的:评估LCIG作为白天的单一疗法的疗效和安全性(定义为16小时LCIG有/没有夜间辅助口服左旋多巴/卡比多巴)先进的PD患者。背景:随着帕金森病(PD)的发展,电动机通过口服左旋多巴症状并不总是控制。治疗运动并发症,患者常常要多个辅助PD治疗;然而,药片数量的增加是与病人的依从性,减少左旋多巴不足可能导致级别需要控制PD症状。持续管理levodopa-carbidopa肠凝胶(LCIG)减少电动机并发症造成口服左旋多巴,可能同时减少药丸的负担。设计/方法:第三阶段,54-week,开放研究先进的PD患者,LCIG管理持续16小时/天;辅助治疗4周后被允许。在这个分析中,患者的安全性和有效性仍保持着白天LCIG单一疗法是评估。结果:324名患者PEG-J位置,248 (76.5%)LCIG白天单一疗法(90名患者没有得到隔夜口服左旋多巴/卡比多巴)。之间的基线特征相似LCIG单一疗法和polytherapy组。患者日间LCIG单一疗法经验减少“关闭”的时间在病人接受polytherapy 4.7 vs 3.6小时。患者增加”“时间没有麻烦5.0 vs 4.1小时的运动障碍和减少“On”时间和麻烦的运动障碍的0.3和0.5小时白天LCIG单方vs polytherapy。 Adverse events (AEs) were reported in 90.7% of patients on LCIG daytime monotherapy and 96.1% of patients receiving polytherapy. The rate of individual non-procedure/device-related AEs were similar between patients receiving LCIG daytime monotherapy or polytherapy, of which nausea, fall, and insomnia were the most prevalent for both groups.Conclusions: Daytime LCIG monotherapy and polytherapy demonstrated similar efficacy and safety profiles in advanced PD patients, suggesting that LCIG monotherapy can provide a more simplified treatment option for appropriate patients.Study Supported by: AbbVie, Inc.Disclosure: Dr. Boyd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc., Teva, Lundbeck, Chrono Therapeutics, Neurocrine and Medical Education Resources. Dr. Boyd has received research support from Michael J. Fox Foundation, NIH/NINDS, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, Vaccinex, AbbVie Inc. Dr. Zadikoff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, USworldMeds, Acadia, UCB, St Jude, Merz, Teva, Lundbeck. Dr. Benesh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Benesh holds stock and/or stock options in AbbVie Inc. Dr. Zamudio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Zamudio holds stock and/or stock options in AbbVie Inc. Dr. Robieson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Robieson has received research support from AbbVie Inc. Dr. Kukreja has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie Inc. Dr. Kukreja holds stock and/or stock options in AbbVie Inc. ER -